$4600 | SAVE $1,150 | Single User
$8050 | SAVE $3,450 | Site License
$10350 | SAVE $6,900 | Enterprise License

HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

Published by Delve Insight: 10 Oct 2017 | 139115 | In Stock

Introduction

DelveInsight’s “HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast for 7 major markets. The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast market, as well as treatment algorithm, current treatments & advancements are included.

The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast, providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast 7MM market size is estimated to be USD XX by 2025. The DelveInsight Report will help in enhanced understanding of the HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

• Understanding historical and forecasted epidemiological data for HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast covering 7MM from 2015-2025.

• Segment level epidemiology and market split for HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast.

• The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast.

• The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast market trends.

• Thorough market distribution based on market share for HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast.

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast market.

• To understand the future market competition in the HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast market and Insightful review of the key market drivers and barriers.

• Organize sales and marketing efforts by identifying the best opportunities for HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Table of Contents
for HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

  • 1. Report Introduction

    2. HIV-associated Lipodystrophy Market Overview at a Glance

    2.1. Total Market Share Distribution of HIV-associated Lipodystrophy for 7 MM in 2016

    2.2. Total Market Share Distribution of HIV-associated Lipodystrophy for 7 MM in 2025

    3. HIV-associated Lipodystrophy

    3.1.1. Overview

    3.1.2. Symptoms

    3.1.3. Pathophysiology

    3.1.4. Staging

    3.1.5. Diagnosis

    3.1.6. Treatment

    4. Epidemiology and Patient Population

    4.1.1. United States

    4.1.1.1. Diagnosed Cases of HIV-associated Lipodystrophy in United States

    4.1.2. Germany

    4.1.2.1. Diagnosed Cases of HIV-associated Lipodystrophy in Germany

    4.1.3. France

    4.1.3.1. Diagnosed Cases of HIV-associated Lipodystrophy in France

    4.1.4. Italy

    4.1.4.1. Diagnosed Cases of HIV-associated Lipodystrophy in Italy

    4.1.5. Spain

    4.1.5.1. Diagnosed Cases of HIV-associated Lipodystrophy in Spain

    4.1.6. United Kingdom

    4.1.6.1. Diagnosed Cases of HIV-associated Lipodystrophy in United Kingdom

    5. Treatment Algorithm

    5.1.1. Treatment Guidelines/Practices

    6. Marketed Drugs for HIV-associated Lipodystrophy

    6.1. Drug 1: Company A

    6.1.1. Drug Description

    6.1.2. Mechanism of Action

    6.1.3. Regulatory Milestones

    6.1.4. Advantages & Disadvantages

    6.1.5. Safety and Efficacy

    6.1.6. Product Profile

    6.1.7. Patent Status

    6.2. Drug 2: Company B

    6.2.1. Drug Description

    6.2.2. Mechanism of Action

    6.2.3. Regulatory Milestones

    6.2.4. Advantages & Disadvantages

    6.2.5. Safety and Efficacy

    6.2.6. Product Profile

    6.2.7. Patent Status

    7. Emerging Therapies

    7.1. Drug 3: Company C

    7.1.1. Description

    7.1.2. Regulatory Milestones

    7.1.3. Advantages & Disadvantages

    7.1.4. Product Profile

    7.1.5. Launch Date

    7.1.6. Clinical Development

    7.1.7. Clinical Pipeline Activity

    7.1.8. Ongoing Trials Information

    7.1.9. Clinical Trial by Phase

    7.2. Drug 4: Company B

    7.2.1. Description

    7.2.2. Regulatory Milestones

    7.2.3. Advantages & Disadvantages

    7.2.4. Product Profile

    7.2.5. Launch Date

    7.2.6. Clinical Development

    7.2.7. Clinical Pipeline Activity

    7.2.8. Ongoing Trials Information

    7.2.9. Clinical Trial by Phase

    8. Overview of Total HIV-associated Lipodystrophy Market (2016 & 2025)

    9. HIV-associated Lipodystrophy: Country-Wise Market Analysis

    9.1. United States

    9.1.1. Historical Market Size (2015-2016)

    9.1.2. Forecasted Market Size (2017-2025)

    9.2. Germany Market Size

    9.2.1. Historical Market Size (2015-2016)

    9.2.2. Forecasted Market Size (2017-2025)

    9.3. France Market Size

    9.3.1. Historical Market Size (2015-2016)

    9.3.2. Forecasted Market Size (2017-2025)

    9.4. United Kingdom Market Size

    9.4.1. Historical Market Size (2015-2016)

    9.4.2. Forecasted Market Size (2017-2025)

    9.5. Spain Market Size

    9.5.1. Historical Market Size (2015-2016)

    9.5.2. Forecasted Market Size (2017-2025)

    9.6. Italy Market Size

    9.6.1. Historical Market Size (2015-2016)

    9.6.2. Forecasted Market Size (2017-2025)

    9.7. Japan Market Size

    9.7.1. Historical Market Size (2015-2016)

    9.7.2. Forecasted Market Size (2017-2025)

    10. Market Drivers

    11. Market Restraints

    12. Appendix

    13. Report Methodology

    14. Consulting Services

    15. Disclaimer

    16. About DelveInsight

    List of Tables

    Table 1: Diagnosed Cases HIV-associated Lipodystrophy in United States (2015-2025)

    Table 2: Diagnosed Cases HIV-associated Lipodystrophy in Germany (2015-2025)

    Table 3: Diagnosed Cases HIV-associated Lipodystrophy in France (2015-2025)

    Table 4: Diagnosed Cases HIV-associated Lipodystrophy in United Kingdom (2015-2025)

    Table 5: Diagnosed Cases HIV-associated Lipodystrophy in Spain (2015-2025)

    Table 6: Diagnosed Cases HIV-associated Lipodystrophy in Italy (2015-2025)

    Table 7: Diagnosed Cases HIV-associated Lipodystrophy in Japan (2015-2025)

    Table 8: List of Marketed Drugs for HIV-associated Lipodystrophy

    Table 9: List of Pipeline Phase III Drugs for HIV-associated Lipodystrophy

    Table 10: Drug 1, Clinical Trials by Zone, 2017

    Table 11: Clinical Trials by Trial status, 2017

    Table 12: Drug 2, Clinical Trials by Zone, 2017

    Table 13: Clinical Trials by Trial status, 2017

    Table 14: Drug 3, Clinical Trials by Zone, 2017

    Table 15: Clinical Trials by Trial status, 2017

    Table 16: United States Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Table 17: Germany Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Table 18: France Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Table 19: United Kingdom Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Table 20: Spain Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Table 21: Italy Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Table 22: Japan Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    List of Figures

    Figure 1: Diagnosed Cases HIV-associated Lipodystrophy in United States (2015-2025)

    Figure 2: Diagnosed Cases HIV-associated Lipodystrophy in Germany (2015-2025)

    Figure 3: Diagnosed Cases HIV-associated Lipodystrophy in France (2015-2025)

    Figure 4: Diagnosed Cases HIV-associated Lipodystrophy in United Kingdom (2015-2025)

    Figure 5: Diagnosed Cases HIV-associated Lipodystrophy in Spain (2015-2025)

    Figure 6: Diagnosed Cases HIV-associated Lipodystrophy in Italy (2015-2025)

    Figure 7: Diagnosed Cases HIV-associated Lipodystrophy in Japan (2015-2025)

    Figure 8: List of Marketed Drugs for HIV-associated Lipodystrophy

    Figure 9: List of Pipeline Phase III Drugs for HIV-associated Lipodystrophy

    Figure 10: Drug 1, Clinical Trials by Zone (%), 2017

    Figure 11: Clinical Trials by Trial status, 2017

    Figure 12: Drug 2, Clinical Trials by Zone (%), 2017

    Figure 13: Clinical Trials by Trial status, 2017

    Figure 14: Drug 3, Clinical Trials by Zone (%), 2017

    Figure 15: Clinical Trials by Trial status, 2017

    Figure 16: United States Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Figure 17: Germany Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Figure 18: France Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Figure 19: United Kingdom Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Figure 20: Spain Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Figure 21: Italy Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    Figure 22: Japan Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

    HIV-associated Lipodystrophy Market (7MM)

    HIV-associated Lipodystrophy Market forecasting

    HIV-associated Lipodystrophy Sales forecasting

    HIV-associated Lipodystrophy Market segments

    HIV-associated Lipodystrophy Epidemiology

    HIV-associated Lipodystrophy Pipeline products and technologies

    HIV-associated Lipodystrophy Competitive landscape

    HIV-associated Lipodystrophy SWOT analysis

    HIV-associated Lipodystrophy Market Driver’s and barriers

    HIV-associated Lipodystrophy Key Companies and Funding

List Of Tables
in HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

Table 1: Diagnosed Cases HIV-associated Lipodystrophy in United States (2015-2025)

Table 2: Diagnosed Cases HIV-associated Lipodystrophy in Germany (2015-2025)

Table 3: Diagnosed Cases HIV-associated Lipodystrophy in France (2015-2025)

Table 4: Diagnosed Cases HIV-associated Lipodystrophy in United Kingdom (2015-2025)

Table 5: Diagnosed Cases HIV-associated Lipodystrophy in Spain (2015-2025)

Table 6: Diagnosed Cases HIV-associated Lipodystrophy in Italy (2015-2025)

Table 7: Diagnosed Cases HIV-associated Lipodystrophy in Japan (2015-2025)

Table 8: List of Marketed Drugs for HIV-associated Lipodystrophy

Table 9: List of Pipeline Phase III Drugs for HIV-associated Lipodystrophy

Table 10: Drug 1, Clinical Trials by Zone, 2017

Table 11: Clinical Trials by Trial status, 2017

Table 12: Drug 2, Clinical Trials by Zone, 2017

Table 13: Clinical Trials by Trial status, 2017

Table 14: Drug 3, Clinical Trials by Zone, 2017

Table 15: Clinical Trials by Trial status, 2017

Table 16: United States Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Table 17: Germany Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Table 18: France Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Table 19: United Kingdom Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Table 20: Spain Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Table 21: Italy Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Table 22: Japan Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

List Of Figures, Charts and Diagrams
in HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

Figure 1: Diagnosed Cases HIV-associated Lipodystrophy in United States (2015-2025)

Figure 2: Diagnosed Cases HIV-associated Lipodystrophy in Germany (2015-2025)

Figure 3: Diagnosed Cases HIV-associated Lipodystrophy in France (2015-2025)

Figure 4: Diagnosed Cases HIV-associated Lipodystrophy in United Kingdom (2015-2025)

Figure 5: Diagnosed Cases HIV-associated Lipodystrophy in Spain (2015-2025)

Figure 6: Diagnosed Cases HIV-associated Lipodystrophy in Italy (2015-2025)

Figure 7: Diagnosed Cases HIV-associated Lipodystrophy in Japan (2015-2025)

Figure 8: List of Marketed Drugs for HIV-associated Lipodystrophy

Figure 9: List of Pipeline Phase III Drugs for HIV-associated Lipodystrophy

Figure 10: Drug 1, Clinical Trials by Zone (%), 2017

Figure 11: Clinical Trials by Trial status, 2017

Figure 12: Drug 2, Clinical Trials by Zone (%), 2017

Figure 13: Clinical Trials by Trial status, 2017

Figure 14: Drug 3, Clinical Trials by Zone (%), 2017

Figure 15: Clinical Trials by Trial status, 2017

Figure 16: United States Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Figure 17: Germany Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Figure 18: France Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Figure 19: United Kingdom Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Figure 20: Spain Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Figure 21: Italy Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Figure 22: Japan Market Size of HIV-associated Lipodystrophy in USD, Million (2015-2025)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

139115 | DIMI0299

Number of Pages

70

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024Summary...
08 Sep 2015 by Global Data USD $8,071 (normally
USD $9,495)
More Info
SAVE 15% today! PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
Orphan Drug Market Access: Payer Insights on the Present and Future
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
14 Oct 2014 by FirstWord Pharma USD $695 More Info
Payer Insights: Hepatitis C
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
26 Sep 2014 by FirstWord Pharma USD $7,900 More Info
Pharma-Patient Engagement: insights from patient opinion leaders
IntroductionTPatients and Pharma want the same thing, but for different reasons. Patients want acces...
20 Jun 2014 by FirstWord Pharma USD $695 More Info
Inside China’s Pharma Sales Force – insights from the frontline
IntroductionIn 2011, China’s pharmaceutical sales force exceeded that of the U.S. for the first time...
01 Jul 2013 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data